Related Experiment Video
Updated: Aug 21, 2026
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
Published on: September 13, 2019
Profiling the molecular difference between Patched- and p53-dependent rhabdomyosarcoma
Roland Kappler1, Regine Bauer, Julia Calzada-Wack
1Institute of Human Genetics, University of Göttingen, Heinrich-Düker-Weg 12, Göttingen, Germany.
Abstract:
Rhabdomyosarcoma (RMS) is a highly malignant tumor that is histologically related to skeletal muscle, yet genetic and molecular lesions underlying its genesis and progression remain largely unknown. In this study we have compared the molecular profiles of two different mouse models of RMS, each associated with a defined primary genetic defect known to play a role in rhabdomyosarcomagenesis in man. We report that RMS of heterozygous Patched1 (Ptch1) mice show less aggressive growth and a greater degree of differentiation than RMS of heterozygous p53 mice. By means of cDNA microarray analysis we demonstrate that RMS in Ptch1 mutants predominantly express a number of myogenic markers, including myogenic differentiation 1, myosin heavy chain, actin, troponin and tropomyosin, as well as genes associated with Hedgehog/Patched signaling like insulin-like growth factor 2, forkhead box gene Foxf1 and the growth arrest and DNA-damage-inducible gene Gadd45a. In sharp contrast, RMS in p53 mutants display higher expression levels of cell cycle-associated genes like cyclin B1, cyclin-dependent kinase 4 and the proliferation marker Ki-67. These results demonstrate that different causative mutations lead to distinct gene expression profiles in RMS, which appear to reflect their different biological characteristics. Our results provide a first step towards a molecular classification of different forms of RMS. If the described differences can be confirmed in human RMS our results will contribute to a new molecular taxonomy of this cancer, which will be critical for gene mutation- and expression-specific therapy.
Insights
Different genetic defects in mouse models create distinct molecular profiles in rhabdomyosarcoma (RMS). Patched1 (Ptch1) mutations lead to differentiated RMS, while p53 mutations result in proliferative RMS, aiding molecular classification.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Rhabdomyosarcoma (RMS) is a malignant skeletal muscle tumor with largely unknown genetic and molecular drivers.
- Understanding these drivers is crucial for developing targeted therapies.
Purpose of the Study:
- To compare the molecular profiles of two distinct mouse models of RMS with defined genetic defects.
- To investigate how different mutations influence RMS biological characteristics and gene expression.
Main Methods:
- Utilized two genetically engineered mouse models of RMS: heterozygous Patched1 (Ptch1) and heterozygous p53.
- Employed cDNA microarray analysis to compare gene expression profiles between the two models.
Main Results:
- RMS in Ptch1 mutants exhibited less aggressive growth and higher differentiation, expressing myogenic and Hedgehog/Patched signaling genes.
- RMS in p53 mutants showed higher proliferation, with increased expression of cell cycle-associated genes and the Ki-67 marker.
- Distinct genetic mutations resulted in significantly different gene expression profiles, correlating with distinct biological behaviors.
Conclusions:
- Different causative mutations in RMS lead to distinct molecular signatures and biological characteristics.
- These findings represent a foundational step towards a molecular classification of RMS.
- Confirmation in human RMS could enable a new molecular taxonomy for developing targeted therapies based on specific mutations and expression profiles.
